Bookmark

Add to MyYahoo RSS

Lantus, Insulin Glargine News

News on Lantus, Insulin Glargine (generic) continually updated from thousands of sources around the net.

4 hrs ago | Pharmaceutical Processing

Mylan Commences Clinical Trials for Generic Versions of Advair Diskus and Insulin Analog to Lantus

Mylan today announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus and its insulin analog to Sanofi's Lantus. In October 2014, Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Mylan Laboratories, Healthcare Industry, Advair Diskus, Fluticasone/Salmeterol (generic), Healthcare Law, Law, Asthma, Health

Fri Sep 12, 2014

Biopharm

European Commission Grants Lilly and Boehringer Ingelheim's Insulin Glargine Product Marketing in EU

The European Commission granted marketing authorization for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents, and children aged two years and above. Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim Alliance.

Comment?

Related Topix: Medicine, Marketing, Diabetes, Health, Insulin (generic), Humulin, Novolin

Wed Sep 10, 2014

Indianapolis Business News

Lilly receives European marketing OK for new insulin

European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent-infringement litigation with French rival Sanofi.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Marketing, Biotech, Eli Lilly, Healthcare Industry, Diabetes, Health

Tue Sep 09, 2014

Business Wire

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce...

Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50 th EASD Annual Meeting 28 abstracts presented, including data on empagliflozin, an SGLT2 inhibitor recently approved in the European Union and in the US as Jardiance A )--Data to be presented at the European Association for the Study of Diabetes Annual Meeting in Vienna, Austria, will add to the extensive clinical evidence supporting the efficacy and safety profile of the diabetes portfolio from the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. In addition, physician insights will be presented from IntroDiaa , the largest global survey of its kind in Type 2 Diabetes .

Comment?

Related Topix: Medicine, Diabetes, Health, Biotech, Eli Lilly, Healthcare Industry, World News, Austria, Metformin (generic), Glucophage

Mon Sep 08, 2014

The Motley Fool

3 Reasons Sanofi's Stock Could Fall

Consequently, its shares have under-performed both the broader markets and the healthcare sector in general, as shown by the chart below. To improve top line growth and return to profitability, Sanofi's CEO Christopher Viehbacher has increasingly leaned on the company's clinical pipeline to replace lost revenues.

Comment?

Related Topix: Food and Drug Administration, Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin, Financial Markets

CiteULike

New insulin glargine 300 U/mL versus glargine 100 U/mL in people with ...

New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial . To compare efficacy and safety of new insulin glargine 300 U/mL with glargine 100 U/mL in people with type 2 diabetes using basal insulin plus oral antihyperglycemic drugs .

Comment?

Related Topix: Medicine, Health, Diabetes, Insulin (generic), Humulin, Novolin

Thu Sep 04, 2014

The Indianapolis Star

Eli Lilly insulin tops Lantus in two tests

Eli Lilly insulin tops Lantus in two tests It's rare for new bio-engineered insulins to show notably better treatment differences against the market leader Check out this story on IndyStar.com: http://indy.st/1rOmPHL Eli Lilly and Co. corporate headquarters at Delaware and McCarty streets in Downtown Indianapolis.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Biotech, Eli Lilly, Healthcare Industry, Diabetes, Health

Applied Clinical Trials

Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority...

Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators Lilly expects U.S. and European regulatory submissions by end of Q1 2015 Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus in Phase III Trials in Patients with Type 1 Diabetes /PRNewswire/ -- Eli Lilly and Company's basal insulin peglispro demonstrated a statistically significant lower hemoglobin A1c compared with insulin glargine at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. Patients in these trials were also taking mealtime insulin.

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Biotech, Eli Lilly, Healthcare Industry

Tue Sep 02, 2014

Seeking Alpha

Sanofi Should Be Part Of Your Portfolio If You Want Higher Returns

Sanofi had a decent second quarter. The company's sales remained stable at $10.65 billion compared with $10.56 billion quarter over quarter.

Comment?

Related Topix: Biotech, SanofiSynthlabo, Medicine, Genzyme General, Healthcare Industry, Diabetes, Health, Marketing

Fri Aug 22, 2014

Drugs.com

FDA Grants Tentative Approval for Lilly and Boehringer...

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration today granted tentative approval for Basaglara , which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes.

Comment?

Related Topix: Eli Lilly, Food and Drug Administration, Ridgefield, CT, Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin

Thu Aug 21, 2014

Hispanic Business

Zealand Pharma A/S - Interim report for H1 2014

Ex-US market roll-out of Lyxumia by Sanofi continues with several new launches in Q2 2014 and additional launches expected over the rest of the year -- Broad-based pipeline progress - internal and external -- LixiLan Phase III trials advanced by Sanofi with completion expected in H2 2015 -- Plans on track for US filing of Lyxumia in Summer 2015 and ... (more)

Comment?

Related Topix: Medicine, Diabetes, Health

Mon Aug 18, 2014

Sys-Con Media

FDA Grants Tentative Approval for Lilly and Boehringer...

Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company and Boehringer Ingelheim's basal insulin, which is intended to provide long-lasting blood sugar control in between meals and during the night.1 Basaglar has the same amino acid sequence as the currently marketed insulin glargine product and was ... (more)

Comment?

Related Topix: Food and Drug Administration, Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin, Biotech, Eli Lilly, Healthcare Industry

Seeking Alpha

Eli Lilly: Strong Future Prospects Will Restore The Company's Financials

Patent expiries of Cymbalta and Evista have strangled Eli Lilly's quarterly performance this time.

Comment?

Related Topix: Biotech, Medicine, Eli Lilly, Healthcare Industry, Diabetes, Health, Pancreatic Cancer

•••
•••
•••
•••
•••
•••
•••